Drug Profile
Influenza virus vaccine - Imaxio
Alternative Names: OPTIVAC projectLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Imaxio
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Influenza virus infections
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in France (Parenteral)
- 14 Jul 2016 Preclinical development is ongoing in France
- 14 Jul 2016 Influenza virus vaccine - Imaxio is available for licensing as of 14 Jul 2016. http://www.imaxio.com/